Watch our informative discussion about recent bispecific antibody therapy options for B-Cell non-Hodgkin lymphomas (NHL), including follicular lymphoma (FL). Whether you’re recently diagnosed or thinking about next steps in your journey, this session will help you understand all the key information about this class of therapeutics.
This webinar is run in partnership with Plexus Communications, and supported by an educational grant from Genentech.Â
Whether you’re living with FL, a family member, caregiver, or healthcare professional, this webinar will provide valuable knowledge and an inspiring personal storyÂ
What we covered – a 101 on bispecific antibodies:
Â
The webinar has been recorded and will be published on our website very soon. Watch our past webinars here.  Â
Stay tuned for more webinars covering other highly requested topics in the coming months!Â
Associate Professor, Department of Hematology and Medical Oncology Co-Director, Lymphoma Program Chair, Data and Safety Monitoring Committee Emory Winship Cancer Institute
Board certified in hematology and medical oncology, Jonathon B. Cohen, MD, MS, treats Hodgkin's and non-Hodgkin's lymphoma patients and is a member of the physician staff at the Bone Marrow and Stem Cell Transplant Center at Winship. Dr. Cohen is a leading expert in CAR T-cell therapy, an emerging new immunotherapy for some forms of lymphoma.
Dr. Cohen has been recognized as a promising young investigator as evidenced by his selection to participate in the ASCO/AACR Methods in Clinical Cancer Research workshop, American Society of Hematology Clinical Research Training Institute, and the Lymphoma Research Foundation Clinical Research Mentorship Program.
Dr. Cohen earned his undergraduate degree at Emory University and received his medical degree at the University of Florida College of Medicine. He completed a residency in internal medicine and fellowship in hematology and medical oncology at The Ohio State University in Columbus, Ohio. During his fellowship, he also completed a master's degree in medical science, gathering additional training in the conduct of clinical and translational research
John Ferris is a retired financial executive, school administrator and entrepreneur from New Hampshire, and a survivor of follicular lymphoma.
Ferris is a retired financial executive, school administrator and entrepreneur from New Hampshire, and a survivor of follicular lymphoma. Diagnosed with stage IV FL in 2018 and initially given just months to live, Ferris' journey took a remarkable turn after rounds of chemo and radiation, when he joined a clinical trial. The trial, which explored bispecific antibody treatment, brought him into remission. He later underwent CART treatment, which, since 2023, has allowed him to maintain full remission. 
Ferris' story is also one of profound personal resilience. Amid dealing with his cancer, he faced a relapse in alcohol addiction, a struggle he overcame with the compassionate support of his oncology team. Today, Ferris is a passionate advocate for sharing patient experiences and for the importance of holistic care — addressing both physical and emotional health challenges.
We’re pleased to have Ferris join this informative webinar, to share his perspective on bispecific antibody therapy in FL.
